Chronic granulomatous disease associated with Duchenne muscular dystrophy caused by Xp21.1 contiguous gene deletion syndrome: Case report and literature review

Chronic granulomatous disease (CGD) and Duchenne muscular dystrophy (DMD) are X-linked recessive disorders whose genes are 4.47 Mb apart within Xp21.1. A combination of both diseases is rare with only five cases reported in the literature where it is known as Xp21.1 “contiguous gene deletion syndrome”. We describe a male neonate who presented with sepsis at 19 days of age. The diagnosis of CGD with DMD was established through copy number variation sequencing (CNV-seq) with an extensive 7.5 Mb deletion of Xp21.2-Xp11.4 of the proband. One of his elder sisters and his mother are carriers. The deletion includes six known genes: glycerol kinase (GK), dystrophin (DMD), cilia- and flagella-associated protein 47 (CFAP47), gp91 (CYBB), Kell antigen (XK), and retinitis pigmentosa GTPase regulator (RPGR). Laboratory assays revealed an increased creatine kinase (CK) level, decreased gp91 expression, and a positive nitroblue tetrazolium test. Due to the extensive gene deletion and the poor prognosis, the family determined to pursue conservative management without further laboratory workup. The patient passed away from a fulminant infection at the age of three-month at a local medical facility. To the best of our knowledge, this case of Xp21.1 contiguous gene deletion syndrome represents the most extensive deletion of genes in this region ever reported. A literature review of similar cases is presented.

[1]  J. L. Shephard,et al.  Hematologically important mutations: X-linked chronic granulomatous disease (fourth update). , 2021, Blood cells, molecules & diseases.

[2]  J. Veltman,et al.  Deleterious variants in X-linked CFAP47 induce asthenoteratozoospermia and primary male infertility. , 2021, American journal of human genetics.

[3]  R. Śmigiel,et al.  Complex glycerol kinase deficiency – long-term follow-up of two patients , 2021, Pediatric endocrinology, diabetes, and metabolism.

[4]  A. Fischer,et al.  Chronic Granulomatous Disease with the McLeod Phenotype: a French National Retrospective Case Series , 2020, Journal of Clinical Immunology.

[5]  B. Lujan,et al.  Retinal gene therapy in X-linked retinitis pigmentosa caused by mutations in RPGR: Results at 6 months in a first in human clinical trial , 2020, Nature Medicine.

[6]  Hong-Yan Ji,et al.  Serum Biomarkers for Early Diagnosis of Chinese X-CGD Children: Case Reports and a Literature Review , 2019, Current Medical Science.

[7]  Hans H. Jung,et al.  Molecular Basis and Clinical Overview of McLeod Syndrome Compared With Other Neuroacanthocytosis Syndromes: A Review , 2018, JAMA neurology.

[8]  H. Shimada,et al.  Cytologic and Ultrastructural Findings of Bronchoalveolar Lavage in Patients With Chronic Granulomatous Disease , 2018, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[9]  J. O'Sullivan,et al.  Stepwise partitioning of Xp21: a profiling method for XK deletions causative of the McLeod syndrome , 2017, Transfusion.

[10]  E. Y. Kim,et al.  Correlation of Serum Creatine Kinase Level With Pulmonary Function in Duchenne Muscular Dystrophy , 2017, Annals of rehabilitation medicine.

[11]  M. Gonçalves,et al.  The emerging role of viral vectors as vehicles for DMD gene editing , 2016, Genome Medicine.

[12]  M. Chiriacò,et al.  Chronic granulomatous disease: Clinical, molecular, and therapeutic aspects , 2016, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[13]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[14]  A. Pathare,et al.  Clinical and molecular findings of chronic granulomatous disease in Oman: family studies , 2015, Clinical genetics.

[15]  C. Ki,et al.  Identification of a Novel Mutation in the CYBB Gene, p.Asp378Gly, in a Patient With X-linked Chronic Granulomatous Disease , 2014, Allergy, asthma & immunology research.

[16]  T. Kizaki,et al.  Copy Number Variations Due to Large Genomic Deletion in X-Linked Chronic Granulomatous Disease , 2012, PloS one.

[17]  M. Yamada,et al.  Determination of the deletion breakpoints in two patients with contiguous gene syndrome encompassing CYBB gene. , 2010, European journal of medical genetics.

[18]  J. V. van Krieken,et al.  Gastrointestinal zygomycosis due to Rhizopus microsporus var. rhizopodiformis as a manifestation of chronic granulomatous disease. , 2008, Medical mycology.

[19]  A. Danek,et al.  McLeod syndrome: a neurohaematological disorder , 2007, Vox sanguinis.

[20]  C. Westhoff,et al.  Insights into extensive deletions around the XK locus associated with McLeod phenotype and characterization of two novel cases. , 2007, Gene.

[21]  P. Tonin,et al.  Complex glycerol kinase deficiency leads to psychomotor and body‐growth failure , 2004, Journal of paediatrics and child health.

[22]  Marie Lin,et al.  Molecular Basis of the Kell-null Phenotype , 2001, The Journal of Biological Chemistry.

[23]  Richard B. Johnston,et al.  Chronic Granulomatous Disease: Report on a National Registry of 368 Patients , 2000, Medicine.

[24]  S. Holland,et al.  Genetic, biochemical, and clinical features of chronic granulomatous disease. , 2000, Medicine.

[25]  P. Gane,et al.  Analysis of deletions in three McLeod patients: exclusion of the XS locus from the Xp21.1-Xp21.2 region. , 2000, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[26]  Duchenne The Pathology of Paralysis with Muscular Degeneration (Paralysie Myosclérotique) , 1867, British medical journal.